Skip to content

Patienthèque of Finisterian (South of Brittany) Children With Cystic Fibrosis in the Time of Precision Medicine

Patienthèque of Finisterian (South of Brittany) Children With Cystic Fibrosis in the Time of Precision Medicine.Descriptive Monocentric Study for Identification and Validation of Biomarkers Predictive of Clinical Evolution

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04137133
Acronym
MUCOthèque
Enrollment
20
Registered
2019-10-23
Start date
2022-03-21
Completion date
2030-03-31
Last updated
2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystic Fibrosis

Brief summary

The objective of this study is to evaluate the relevance of Porphyromonas as a biomarker predicting the risk of P. aeruginosa primocolonization in children form 0 to 18 years old with cystic fibrosis.

Detailed description

This is a monocentric study in 3 phases: * Pre-inclusion: at the first visit to the CRCM (support for a positive screening confirmed by sweat test and genotyping CFTR) * Inclusion: possible between the 2nd visit to the CRCM (about 2 months old) and the 6th month * Follow-up: up to 36 months old. The pace of visits will be based on the usual follow-up rate of CF infants Clinical and paraclinical data and samples will be collected as part of the usual follow-up of CF children. Inclusions and follow-up visits will be carried out at the Roscoff CRCM as well as respiratory explorations and biological samples. Dermatological and odontological follow-ups will be scheduled for each patient at the rate of an annual visit to the CHRU in Brest in the relevant departments.

Interventions

DIAGNOSTIC_TESTcollection

bronchial secretions, blood, stools, superficial skin sample, dental plaque sample and urine

Sponsors

University Hospital, Brest
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
No minimum to 18 Years
Healthy volunteers
No

Inclusion criteria

* Newly screened infants with a confirmed diagnosis of cystic fibrosis in its classic form (clinical symptoms and two positive sweat tests and/or two mutations of the cftr gene from Class I to III) * Children free of any colonization with P. aeruginosa * Affiliation with the social security system * Consent signed by the holders of parental authority or the sole parent holding parental authority

Exclusion criteria

* Children colonized with P. aeruginosa according to the cytobacteriological examination and / or molecular test of sputum or pharyngeal specimens * Children grafted * Children not affiliated to a social security scheme or not entitled to * Children whose parent (s) are (are) minor (s) * Children whose holders of parental authority do not master the French language * Refusal to participate in the study

Design outcomes

Primary

MeasureTime frameDescription
Presence of P. aeruginosa in bacterial sputum cultures in one of bronchial secretions sample3 yearsAnalyse with Porphyromonas predictive biomarker of the risk of P. aeruginosa primocolonization.

Countries

France

Contacts

Primary ContactGeneviève HERY-ARNAUD
Genevieve.Hery-Arnaud@univ-brest.fr0298145102

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026